Unicycive Therapeutics Inc
UNCY | $1.15 57K
|
Professional, Scientific, and T...
(0.0% 1d) (-24.3% 1m) (-26.8% 1y) (0.0% 2d) (0.0% 3d) (-0.9% 7d) (98.55% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 39,969,901
https://unicycive.com
Sec Filling | Patents | 2021 employees
Unicycive is a biotechnology company developing novel treatment for kidney diseases. Unicycive's lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent protected new chemical entity in late preclinical development for the treatment of acute kidney injury.
treatment kidney
add to watch list Paper trade email alert is off
Press-releases
Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
Published: 2024-04-10 (Crawled : 11:00) - globenewswire.com
UNCY | $1.15 57K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 0.0%
C: -1.52%
conference therapeutics growth
Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update
Published: 2024-03-28 (Crawled : 20:00) - globenewswire.com
UNCY | $1.15 57K
|
Professional, Scientific, and T...
| Email alert
Add to watchlist
business year update financial results
Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress
Published: 2024-03-25 (Crawled : 11:00) - globenewswire.com
UNCY | $1.15 57K
|
Professional, Scientific, and T...
|
| O: 1.36%
H: 7.38%
C: 2.01%
congress association renal therapeutics
Unicycive Announces $50 Million Private Placement
Published: 2024-03-14 (Crawled : 11:00) - globenewswire.com
UNCY | $1.15 57K
|
Professional, Scientific, and T...
|
| O: 8.63%
H: 14.57%
C: -4.64%
million
Unicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT Conference
Published: 2024-03-13 (Crawled : 11:00) - globenewswire.com
UNCY | $1.15 57K
|
Professional, Scientific, and T...
|
| O: 1.75%
H: 1.03%
C: -4.47%
uni-494 conference presentation therapeutics
Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)
Published: 2024-03-07 (Crawled : 21:00) - globenewswire.com
UNCY | $1.15 57K
|
Professional, Scientific, and T...
|
| O: -6.67%
H: 10.71%
C: 8.57%
trial therapeutics
Unicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the U.S. Food and Drug Administration for the Prevention of Delayed Graft Function in Kidney Transplant Patients
Published: 2024-03-04 (Crawled : 12:00) - globenewswire.com
UNCY | $1.15 57K
|
Professional, Scientific, and T...
|
| O: 1.25%
H: 2.46%
C: -8.02%
uni-494 drug kidney granted food designation therapeutics
Unicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meeting
Published: 2024-02-14 (Crawled : 12:00) - globenewswire.com
UNCY | $1.15 57K
|
Professional, Scientific, and T...
|
| O: 3.81%
H: 7.34%
C: 6.42%
kidney spring meeting therapeutics
Unicycive Therapeutics Announces Both an Oral and Poster Presentation to be Delivered on UNI-494 at the Upcoming AKI and CRRT Conference
Published: 2024-01-29 (Crawled : 12:00) - globenewswire.com
UNCY | $1.15 57K
|
Professional, Scientific, and T...
|
| O: 5.73%
H: 3.24%
C: 1.61%
uni-494 conference presentation therapeutics
Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestones
Published: 2024-01-23 (Crawled : 12:00) - globenewswire.com
UNCY | $1.15 57K
|
Professional, Scientific, and T...
|
| O: 4.69%
H: 20.69%
C: 12.99%
key therapeutics
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 89% | 11% |
Top 10 Gainers
MTTR | News M | $4.65 167.24% 9.8M
|
AGBA | $2.46 96.8% 28M
|
Finance
EDBL | News | $6.94 84.57% 1.4M
|
CZOO | $7.74 55.11% 2.7M
|
VNRX | $0.84 40.0% 2.6M
|
Health Technology
OPRT | News | $3.01 33.78% 6.8M
|
Finance
MLEC | $1.81 29.29% 2M
|
n/a
MTC | $2.0 28.21% 1.7M
|
Technology Services
PEGY | $0.0586 27.95% 130M
|
Manufacturing
BTCM | $3.41 26.3% 230K
|
Arts, Entertainment, and Recrea...
Last 48 Hours Insiders Buying
TPL P 3 | $585.25 -0.1% 4.7K
|
Miscellaneous
|
15:00
ETST P 79000 | $0.065 110K
|
Manufacturing
|
11:30
MCFT P 26039 | $22.0 2.33% 29K
|
Consumer Durables
|
00:00
YORW P 29 | $35.6 0.51% 11K
|
Utilities
|
19:01
VUZI P 14500 | $1.34 -0.74% 84K
|
Electronic Technology
|
17:00
BANF P 256 | $92.43 1.26% 5.7K
|
Finance
|
15:30
RMCF | $3.57 170
|
Consumer Non-Durables
|
20:10